- Home
- DOGZ vs ALLO Comparison
DOGZ vs ALLO Comparison
Compare DOGZ & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOGZ
- ALLO
- Stock Information
- Founded
- DOGZ 2003
- ALLO 2017
- Country
- DOGZ China
- ALLO United States
- Employees
- DOGZ N/A
- ALLO N/A
- Industry
- DOGZ Miscellaneous manufacturing industries
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DOGZ Consumer Discretionary
- ALLO Health Care
- Exchange
- DOGZ Nasdaq
- ALLO Nasdaq
- Market Cap
- DOGZ N/A
- ALLO 338.9M
- IPO Year
- DOGZ 2017
- ALLO 2018
- Fundamental
- Price
- DOGZ $25.09
- ALLO $1.46
- Analyst Decision
- DOGZ
- ALLO Strong Buy
- Analyst Count
- DOGZ 0
- ALLO 10
- Target Price
- DOGZ N/A
- ALLO $9.66
- AVG Volume (30 Days)
- DOGZ 77.6K
- ALLO 3.5M
- Earning Date
- DOGZ 05-16-2025
- ALLO 05-12-2025
- Dividend Yield
- DOGZ N/A
- ALLO N/A
- EPS Growth
- DOGZ N/A
- ALLO N/A
- EPS
- DOGZ N/A
- ALLO N/A
- Revenue
- DOGZ $20,258,926.00
- ALLO $22,000.00
- Revenue This Year
- DOGZ N/A
- ALLO N/A
- Revenue Next Year
- DOGZ N/A
- ALLO $8.30
- P/E Ratio
- DOGZ N/A
- ALLO N/A
- Revenue Growth
- DOGZ 46.16
- ALLO N/A
- 52 Week Low
- DOGZ $5.40
- ALLO $1.23
- 52 Week High
- DOGZ $58.50
- ALLO $4.25
- Technical
- Relative Strength Index (RSI)
- DOGZ 41.66
- ALLO 34.84
- Support Level
- DOGZ $26.00
- ALLO $1.32
- Resistance Level
- DOGZ $30.39
- ALLO $1.47
- Average True Range (ATR)
- DOGZ 2.64
- ALLO 0.13
- MACD
- DOGZ -0.10
- ALLO -0.02
- Stochastic Oscillator
- DOGZ 8.79
- ALLO 13.64
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.